Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MRG002 in HER2-low advanced or metastatic breast cancer
CTR20210235Phase 2Completed
- Sponsor
- Hangzhou Miracogen
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002 in breast cancer, sponsored by Hangzhou Miracogen. Started Jun 2021; status: completed.
02
Drugs
MRG002
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20210235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210235.